



**Van:** 5.1.2e <5.1.2e@minvws.nl>

**Verzonden:** donderdag 1 oktober 2020 21:24

**Aan:** 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e @rivm.nl; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e @rivm.nl; 5.1.2e @rivm.nl; 5.1.2e @rivm.nl

**Onderwerp:** RE: Invitation to scientific meeting with Moderna

Beste collega's,

Zoals eerder besproken juich ik het toe als het RIVM direct contact opneemt met de producenten voor wetenschappelijke achtergrond. Weet – en dat is vertrouwelijk- dat de contractonderhandelingen niet echt heel erg soepel lopen. We hebben daar nog een lange weg te gaan en de kans op falen is aanwezig.

Hartelijke groet,

5.1.2e

**Van:** 5.1.2e <5.1.2e@minvws.nl>

**Verzonden:** donderdag 1 oktober 2020 20:51

**Aan:** 5.1.2e @rivm.nl; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e @rivm.nl; 5.1.2e @rivm.nl; 5.1.2e @rivm.nl; 5.1.2e @rivm.nl; 5.1.2e @minvws.nl

**Onderwerp:** RE: Invitation to scientific meeting with Moderna

Lijkt me prima zo hun aanbod aan mij op te pakken, dus reageer gerust namens mij en zet mij svp in cc (5.1.2e final check zijn er vanuit de onderhandelingen JNT redenen om het niet te doen?

Verzonden met BlackBerry Work([www.blackberry.com](http://www.blackberry.com))

**Van:** 5.1.2e <5.1.2e@rivm.nl>

**Verzonden:** 30 sep. 2020 20:01

**Aan:** "5.1.2e <5.1.2e@rivm.nl>" <5.1.2e@minvws.nl>; "5.1.2e <5.1.2e@rivm.nl>" <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>

**Onderwerp:** RE: Invitation to scientific meeting with Moderna

Hallo 5.1.2e

Zoals eerder aangegeven willen wij graag de potentiële leveranciers uitnodigen om meer praktisch kennis over de betreffende producten te verkrijgen. Komende vrijdag beginnen we met Pfizer, hoewel dit geen wetenschappelijke update wordt, maar meer een praktische sessie i.v.m. opslag en distributie. Als jullie akkoord zijn, nodigen wij Moderna uit.

m.vr.gr.

5.1.2e

**From:** 5.1.2e <5.1.2e@minvws.nl>

**Sent:** woensdag 30 september 2020 13:18

**To:** 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>

**Subject:** FW: Invitation to scientific meeting with Moderna

Nou ze blijven aandringen, zou ze graag naar RIVM sturen, wie? Wellicht kunnen jullie kort concept antwoord maken? Groet, 5.1.2e

**Van:** 5.1.2e <5.1.2e@modernatx.com>

Verzonden: dinsdag 29 september 2020 14:08

Aan: [REDACTED] <[REDACTED]@minvws.nl>  
 CC: [REDACTED] <[REDACTED]@modernatx.com>; [REDACTED] <[REDACTED]@modernatx.com>  
 Onderwerp: Re: Invitation to scientific meeting with Moderna

Dear Mr. [REDACTED]

I hope you are well.

Following Mr. [REDACTED] kind introduction, we would like to again express that the Moderna team would be happy to meet with you or your broader team to discuss the science and data behind mRNA-1273. Do let us know if this would be of interest, and / or if you have any questions.

Best wishes,

[REDACTED]

---

From: [REDACTED] <[REDACTED]@[REDACTED]>  
 Sent: Thursday, September 24, 2020 12:50 PM  
 To: [REDACTED] <[REDACTED]@modernatx.com>  
 Cc: [REDACTED] <[REDACTED]@gmail.com>; [REDACTED] <[REDACTED]@minvws.nl> <[REDACTED]@minvws.nl>  
 Subject: RE: Invitation to scientific meeting with Moderna

**ALERT: This message originated outside of Moderna's network. BE CAUTIOUS before clicking any link or attachment.**

I copy Mr. [REDACTED] of NL Ministry of Health; who can address your questions/topics.

---

From: [REDACTED] <[REDACTED]@modernatx.com>  
 Sent: Thursday, September 24, 2020 5:55 PM  
 To: [REDACTED] <[REDACTED]@[REDACTED]>; [REDACTED] <[REDACTED]@modernatx.com>  
 Cc: [REDACTED] <[REDACTED]@gmail.com>  
 Subject: RE: Invitation to scientific meeting with Moderna

**CAUTION - This email originated from outside** [REDACTED]  
 Please forward suspicious emails as attachments to [REDACTED] <[REDACTED]>

Dear Mr. [REDACTED],

On behalf of [REDACTED] we would like to thank you very much for your response.

We are indeed in touch with the European Commission on an ongoing basis, and wished to offer an additional opportunity to you and your colleagues to answer any scientific questions you may have relating to our vaccine candidate mRNA-1273.

Kind Regards,

[REDACTED]

---

From: [REDACTED] <[REDACTED]@[REDACTED]>  
 Sent: Tuesday, September 22, 2020 10:50 AM  
 To: [REDACTED] <[REDACTED]@modernatx.com>  
 Cc: [REDACTED] <[REDACTED]@gmail.com>  
 Subject: RE: Invitation to scientific meeting with Moderna

**ALERT: This message originated outside of Moderna's network. BE CAUTIOUS before clicking any link or attachment.**

Thanks

I suppose you are in contact with [REDACTED] 5.1.2e of the European Commission?  
She is leading the vaccines on behalf of Europe

[REDACTED] 5.1.2e

---

**From** [REDACTED] 5.1.5 [REDACTED] 5.1.2e <[REDACTED]@modernatx.com>

**Sent:** Monday, September 21, 2020 7:48 PM

**To:** [REDACTED] 5.1.5 [REDACTED] 5.1.2e <[REDACTED]@modernatx.com>; [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @ [REDACTED] 5.1.2e

**Cc:** [REDACTED] 5.1.2e <[REDACTED]@gmail.com>

**Subject:** RE: Invitation to scientific meeting with Moderna

**CAUTION** - This email originated from outside [REDACTED] 5.1.2e  
Please forward suspicious emails as attachments to [REDACTED] 5.1.2e @ [REDACTED] 5.1.2e

Dear Mr. [REDACTED] 5.1.2e,

I hope this finds you well.

Following-up on your previous exchange with [REDACTED] 5.1.2e I wanted to enquire if there is any interest with you or your broader team to discuss the science and data behind mRNA-1273. We would be delighted to hear your views and answer any questions you may have regarding the role our vaccine candidate could play in a portfolio of solutions to address the current crisis.

Kind Regards,

[REDACTED] 5.1.2e

---

**From** [REDACTED] 5.1.5 [REDACTED] 5.1.2e <[REDACTED]@modernatx.com>

**Sent:** Wednesday, September 9, 2020 11:46 AM

**To:** [REDACTED] 5.1.2e @ [REDACTED] 5.1.2e

**Cc:** [REDACTED] 5.1.2e <[REDACTED]@gmail.com>

**Subject:** Invitation to scientific meeting with Moderna

Dear Mr. [REDACTED] 5.1.2e,

I hope this finds you well.

I am pleased to extend the attached invitation to you for a meeting at your convenience as we reach a number of crucial milestones in the development of our vaccine candidate mRNA-1273 furthering our goal of bringing mRNA technology to the benefit of European and global citizens in the fight against COVID-19.

I would like to offer our availability to meet with you and your team, to share insights into the science and data behind mRNA-1273, hear your views and answer any questions you may have regarding the role our vaccine candidate could play in a portfolio of solutions to address the current crisis.

The Moderna team and I very much look forward to the opportunity to bring our mRNA technology to Europe.

Thank you in advance for your time and consideration.

Kind Regards,

[REDACTED] 5.1.2e

[\[REDACTED\]@modernatx.com](mailto:[REDACTED]@modernatx.com)

**moderna**



Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

---

DISCLAIMER:

This e-mail is for the intended recipient only.

If you have received it by mistake please let us know by reply and then delete it from your system; access, disclosure, copying, distribution or reliance on any of it by anyone else is prohibited.

If you as intended recipient have received this e-mail incorrectly, please notify the sender (via e-mail) immediately.

---

DISCLAIMER:

This e-mail is for the intended recipient only.

If you have received it by mistake please let us know by reply and then delete it from your system; access, disclosure, copying, distribution or reliance on any of it by anyone else is prohibited.

If you as intended recipient have received this e-mail incorrectly, please notify the sender (via e-mail) immediately.

Confidentiality Notice:

This email and any attachments may be confidential and protected by legal privilege. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the e-mail or any attachment is prohibited. If you have received this email in error, please notify us immediately by replying to the sender and then delete this copy and the reply from your system. Thank you for your cooperation.

FTI Consulting Belgium SA. A member of FTI Consulting Inc. Registered at Avenue Marnix 23, 1000 Brussels, Belgium. RCB. VAT BE 0478 948 485

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

[www.rivm.nl](http://www.rivm.nl) De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

[www.rivm.nl/en](http://www.rivm.nl/en) Committed to *health and sustainability*